BLTE Belite Bio
- 43.200
- +2.100+5.11%
- 43.200
- 0.0000.00%
Belite Bio News
Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
Tinlarebant is Belite Bio's orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration
Belite Bio Unveils Plan to Offer 651,380 American Depository Shares
Belite Bio (BLTE) said late Thursday it is planning to sell up to 651,380 American depositary shares at $38.38 per ADS in a registered direct offering. The company also plans to sell warrants to purch
Belite Bio Prices $25M Direct Offering
Reported Earlier, Belite Bio Secures $25M In Registered Direct Offering With Institutional Investors
Belite Bio entered into a securities purchase agreement with an institutional investor, for the purchase and sale of up to an aggregate of 651,380 American Depositary Shares of the Company ("ADSs"), e
Belite Bio Announces $25 Million Registered Direct Offering
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio" or the "Company"), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting
Belite Bio Is Maintained at Buy by HC Wainwright & Co.
Belite Bio Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Belite Bio, Maintains $59 Price Target
HC Wainwright & Co. analyst Yi Chen maintains Belite Bio with a Buy and maintains $59 price target.
Buy Rating Affirmed on Belite Bio as Tinlarebant Shows Promising Clinical Advancements and Market Potential
Belite Bio Advances Retinal Disease Treatment
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
Tinlarebant is Belite Bio's orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration
Buy Rating Justified for Belite Bio, Inc. ADR Amidst Promising DRAGON Trial Progress and Strong Financials
We're Hopeful That Belite Bio (NASDAQ:BLTE) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success wi
Here's Why We're Not Too Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn Situation
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Arcellx Inc (ACLX) and AdaptHealth (AHCO)
Analysts' Top Healthcare Picks: Belite Bio, Inc. ADR (BLTE), Catalyst Pharma (CPRX)
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Belite Bio, Inc. ADR (BLTE) and Prothena (PRTA)
Earnings Call Summary | Belite Bio(BLTE.US) Q4 2023 Earnings Conference
The following is a summary of the Belite Bio, Inc (BLTE) Q4 2023 Earnings Call Transcript:Financial Performance:No financial performance details provided during the earnings call.Business Progress:Bel
Belite Bio's Q4 Loss Narrows
Belite Bio (BLTE) reported late Monday a Q4 net loss of $0.25 per ordinary share, compared with the $0.27 loss per share a year earlier. Five analysts polled by Capital IQ expected a loss of $0.30 per
Belite Bio GAAP EPS of -$0.25 Beats by $0.05
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerati
Analysis
Price Target
No Data
